T

TriSalus Life Sciences Inc
NASDAQ:TLSI

Watchlist Manager
TriSalus Life Sciences Inc
NASDAQ:TLSI
Watchlist
Price: 7.31 USD 0.07% Market Closed
Market Cap: 365.2m USD

TriSalus Life Sciences Inc
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

TriSalus Life Sciences Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
T
TriSalus Life Sciences Inc
NASDAQ:TLSI
Interest Income Expense
-$2.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
N
Nextdoor Holdings Inc
NYSE:KIND
Interest Income Expense
$24.4m
CAGR 3-Years
396%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Solid Power Inc
NASDAQ:SLDP
Interest Income Expense
$17.6m
CAGR 3-Years
N/A
CAGR 5-Years
153%
CAGR 10-Years
N/A
Core Scientific Inc
NASDAQ:CORZ
Interest Income Expense
-$39.8m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Symbotic Inc
NASDAQ:SYM
Interest Income Expense
$4.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Rumble Inc
NASDAQ:RUM
Interest Income Expense
-$176.6m
CAGR 3-Years
-293%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

TriSalus Life Sciences Inc
Glance View

Market Cap
364.7m USD
Industry
N/A

TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.

TLSI Intrinsic Value
4.98 USD
Overvaluation 32%
Intrinsic Value
Price
T

See Also

What is TriSalus Life Sciences Inc's Interest Income Expense?
Interest Income Expense
-2.7m USD

Based on the financial report for Dec 31, 2024, TriSalus Life Sciences Inc's Interest Income Expense amounts to -2.7m USD.

What is TriSalus Life Sciences Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
32%

Over the last year, the Interest Income Expense growth was 32%.

Back to Top